Briacell Therapeutics Corp

NASDAQ BCTX

Data sourced from iex and EODHD
Download Data

Briacell Therapeutics Corp EBITDA for the quarter ending January 31, 2024: USD -9.88 M

Briacell Therapeutics Corp EBITDA is USD -9.88 M for the quarter ending January 31, 2024, a -413.38% change year over year. EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, measures a company's operating performance by excluding non-operating expenses.
  • Briacell Therapeutics Corp EBITDA for the quarter ending January 31, 2023 was USD 3.15 M, a 43.17% change year over year.
  • Briacell Therapeutics Corp EBITDA for the quarter ending January 31, 2022 was USD 2.20 M, a 1,097.93% change year over year.
  • Briacell Therapeutics Corp EBITDA for the quarter ending January 31, 2021 was USD 183.87 K, a -63.59% change year over year.
  • Briacell Therapeutics Corp EBITDA for the quarter ending January 31, 2020 was USD 504.95 K, a 142.30% change year over year.
NASDAQ: BCTX

Briacell Therapeutics Corp

CEO Dr. William V. Williams M.D.
IPO Date Feb. 24, 2021
Location Canada
Headquarters Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
Employees 16
Sector Healthcare
Industry Biotechnology
Description

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email